InMed Provides Update on Management Changes
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
Pharmaceutical
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines...
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies...
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance...
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12)...
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - -...
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical...
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Velocity Clinical Research expands to UK
From right to left: Shivagami Muthiah, Business Director of Egin Research; Dr. Ahmed Elshashai, Chief Investigator at Egin Research; Dominic...
Saniona publishes its interim report for the third quarter of 2022
Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue...
XIL Health Executive, Alexandra Robertson, Honored in the 2022 OBJ C-Suite Awards
Robertson recognized for developing innovative pharmatech and launching a new Orlando-based company mid-pandemicORLANDO, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) --...
Sirona Biochem Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is...
BioCorRx Provides Business Update for the Third Quarter of 2022
ANAHEIM, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences
JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused...
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a...
Todos Medical Announces Third Quarter 2022 Financial Results
§ 89% increase in Q3/2022 quarterly revenues as compared with Q3/2021 § Earnings and business update call to be held at 8:30am...
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused...
Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform
Company Will Pursue Drug Discovery of Market-Authorized, Finished Pharmaceuticals that Address Demand for Personalized TherapiesFRANKFURT AM MAIN, Germany, Nov. 15,...
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update
-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median...